Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ars Arthro AG

This article was originally published in Start Up

Executive Summary

Ars Arthro's technology, called CaReS, is a cartilage regeneration system that uses harvested cartilage cells which are isolated, then immediately imbedded in a collagen matrix, and then incubated to create a replacement product that can be shaped or molded by surgeons for a precise fit to fix cartilage defects.

You may also be interested in...



Ars Arthro: Taking Tissue Engineering one Step at a Time

Tissue engineering is one of the most promising technology opportunities in orthopedics. But for the companies that have pursued it, the biological process has become something of a waiting game.

Biocoatings: Not Just the Icing on the Cake

The successful commercialization of drug-eluting stents (DES) has done much to pave the way for the biocoating industy. DES not only helped establish a new regulatory body to facilitate device-drug reviews, the FDA Office of Combination Products, they also proved that biocoated devices could take market share from uncoated products, command premium pricing and premium reimbursement.

Medical Device Start-Ups in Germany

Despite the important role that French, German, and other European physicians play in developing and trialing new technology, and the equally important role that EU regulators play in offering a quick path to commercialization, the number of native European medical device companies is surprisingly small. There are hints that the bleak devicie picture might be brightening, however.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT037291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel